1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
WPD Pharmaceuticals Inc.

WPD Pharmaceuticals Inc.

WPDPF
WPD Pharmaceuticals Inc.US flagOther OTC
0.00
USD
-NaN
- -
140.00Market Cap
WPD Pharmaceuticals Inc.
WPDPF
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2019
2020
2022
2023
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.02
-2.13
-3.83
-2.55
-1.68
-1.06
-1.07
-0.55
-0.2
-1.87
-1.76
-0.91
-84.99
- -
0.85
-0.02
- -
Basic EPS, GAAP
-0.01
-1.27
-2.73
-2.61
-1.32
-0.94
-1.12
-0.2
- -
-0.66
-3.08
-0.9
-1.72
- -
-0.76
-0.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.06
-2.15
-5.69
-7.13
-8.52
-9.57
-10.52
-10.48
-10.66
-12.53
0.85
1.01
23.34
- -
-1.07
-1.09
-0.04
Book Value per Share
13.49
8.59
6.75
3.42
2.02
1.06
-0.02
-0.31
-0.51
-2.32
1.29
1.14
21.09
- -
-0.11
-0.12
-0.01
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
- -
5
5
114
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-1
-12
- -
4
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
1
2
- -
- -
- -
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
1
1
- -
- -
- -
- -
- -
- -
- -
- -
1
3
1
- -
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-102.99
- -
-0.78
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-145.08
-572.45
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
5
5
5
Market Capitalization
1
1
4

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
220.81%
49.95%
16.12%
Free Cash Flow
- -
- -
-94.08%
Net Income, GAAP
- -
- -
-102.08%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.01
-0.01
- -
-0.01
0.85
2023
- -
- -
- -
- -
-0.02
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
Similar Companies
20/20 GeneSystems Inc. (TWTG)
Iovance Biotherapeutics, Inc. (IOVA)
Circio Holding ASA (CRNA.OL)
Emmaus Life Sciences, Inc. (EMMA)
Oxford BioDynamics Plc (OXBOF)
Antengene Corporation Limited (6996.HK)
Business
WPD Pharmaceuticals Inc. (CSE: WBIO, FSE: 8SV1, OTC: WPDPF) operates as a holding company with no active business operations; its sole asset consists of a minority equity stake, currently approximately 4%, in WPD Pharmaceuticals S.A. (formerly WPD Pharmaceuticals Sp. z o.o.), a Polish biotechnology research and development firm focused on oncology therapies involving biological compounds and small molecules for brain cancers such as glioblastoma multiforme (GBM), leukemia, melanoma, and pediatric brain tumors. The Polish entity previously licensed novel drug candidates including WPD101 (IL-13 and EphA2 receptor-targeted radionuclide therapy), Berubicin (anthracycline for recurrent GBM), Annamycin (liposomal formulation for AML and soft tissue sarcoma lung metastases), WP1066 (STAT3 inhibitor for medulloblastoma and diffuse intrinsic pontine gliomas), and WP1122 (prodrug with antiviral and anticancer potential); these originated from collaborations with institutions like Wake Forest University Health Sciences, MD Anderson Cancer Center, Mayo Clinic, Emory University, and Moleculin Biotech Inc., targeting markets in 30 European and Asian countries plus Russia. Founded in 2006 and headquartered in Vancouver, British Columbia, Canada, the company lost control of its former Polish subsidiary through a restructuring on November 25, 2022, reducing its ownership from full control to a non-controlling interest. Recent developments include a proposed share consolidation announced December 5, 2024 with record date December 24, 2024; debt settlements for common shares in June and July 2024; full revocation of a cease trade order on May 16, 2024; a letter of intent signed August 9, 2023 with ACRX Investments Limited; a convertible debenture offering and pipeline update on May 1, 2023; and further investment by ACRX into WPD Poland on February 13, 2025, diluting WPD's stake while the company seeks funding for potential biopharmaceutical, healthcare, or technology acquisitions.

Company News

APIChatGPT

  • newsfilecorp.com

    CSE Bulletin: Reinstatement - WPD Pharmaceuticals Inc. (WBIO)

  • newsfilecorp.com

    CSE Bulletin: Reinstatement - WPD Pharmaceuticals Inc. (WBIO)